Generic Ozempic Is Coming to Canada

There has been a lot of misinformation spread about GLP-1 medications on social media. The WHO formally recommended GLP-1 therapies for obesity treatment in December 2025, and Health Canada expanded Ozempic’s indication in March 2026 to cover cardiovascular risk reduction in diabetic patients. Studies have shown meaningful reductions in body weight, improved glycemic control, slower kidney disease progression, and fewer major cardiovascular events. These are hard outcomes, rigorously studied. The patients who have been going without this drug because of cost have been paying a real clinical price for that gap. Cheaper access matters. It can save lives.

But the surge in demand that follows generic approval will not be neatly limited to the patients for whom this evidence was built.

Family physicians already report that GLP-1 medications come up daily, often from patients who don’t meet clinical criteria. People wanting to lose 10 or 15 pounds. People who have seen the drug on social media and arrived at the appointment having already decided what they need. Social media has made this out to be a magic drug that drops weight, but this is hardly the case. With price no longer a barrier, that pressure will intensify. The question of who gets this medication, and why, is going to land squarely on the desks of primary care physicians who are already stretched thin.

Semaglutide carries a real side effect profile that includes nausea, vomiting, diarrhea, stomach pain, fatigue, and constipation are common. Because of these, many patients tend to discontinue it over time. And the risk-benefit calculation that justifies the drug in a patient with obesity, type 2 diabetes, and cardiovascular disease looks very different in a patient who is otherwise healthy and just wants weight loss.

There is also the question of what happens when patients stop. For many people, GLP-1 therapy is not a short course, it’s a chronic medication. Stopping typically means regaining the weight.

Meanwhile, lower prices will almost certainly fuel a new wave of online prescribing platforms operating in grey areas, some legitimate, some not. Health Canada has already issued warnings about fake and unauthorized GLP-1 products circulating in Canada. Generic semaglutide at $100 a month will be a powerful commercial draw, and not every service offering it will be doing the clinical work that should accompany the prescription.

The arrival of affordable generic semaglutide is a net gain for Canadian patients. That is not in serious dispute. The patients who have spent years being told that an effective treatment exists but being unable to afford it deserve access, and they are going to get it. That is worth something real.

The worry here is that that we are treating this like a consumer product launch rather than a public health inflection point. The conversation is dominated by price comparisons and market dynamics. What is not being asked enough is: Are our primary care systems resourced to handle the surge? Do we have enough endocrinologists, obesity medicine specialists, and dietitians to support patients on these medications appropriately? Does our insurance infrastructure know how to distinguish medically necessary prescriptions from cosmetic ones? The answer to most of those questions is no. And that is not the drug’s fault. That is a systemic problem that cheaper medication alone will not solve.

Primary care is already under pressure. Obesity medicine specialists and endocrinologists have long waitlists. Dietitians and behavioural health supports, the care that makes GLP-1 therapy most effective, are not freely accessible. The clinical guidelines for prescribing to the new wave of patients walking in from a $100/month price point are not as clear as they need to be.

Access without the infrastructure to support it is not the same as a problem solved. It just shifted into a new problem. The drug is here. The question is whether Canadian healthcare is prepared to use it well, for every patient sitting across the desk, not just the ones who fit neatly into a clinical trial.